Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS)”

19 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 19 of 19 results

Testing effectiveness (Phase 2)Study completedNCT03181399
What this trial is testing

Diet Treatment Glucose Transporter Type 1 Deficiency (G1D)

Who this might be right for
GLUT1DS1EpilepsyGlut1 Deficiency Syndrome 1, Autosomal Recessive+4 more
University of Texas Southwestern Medical Center 45
Early research (Phase 1)Study completedNCT02018315
What this trial is testing

Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D)

Who this might be right for
Glucose Transporter Type 1 Deficiency SyndromeGLUT1 Deficiency Syndrome
Juan Pascual 14
Large-scale testing (Phase 3)Ended earlyNCT02960217
What this trial is testing

Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)

Who this might be right for
Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Ultragenyx Pharmaceutical Inc 44
Not applicableEnrolling By InvitationNCT03655223
What this trial is testing

Early Check: Expanded Screening in Newborns

Who this might be right for
Spinal Muscular AtrophyFragile X SyndromeFragile X - Premutation+182 more
RTI International 30,000
Not applicableTemporarily pausedNCT04137692
What this trial is testing

Red Blood Cell Exchange Transfusion as a Novel Treatment for GLUT1 Deficiency Syndrome

Who this might be right for
Glucose Transporter Type 1 Deficiency SyndromeGLUT1DS1
Weill Medical College of Cornell University 12
Testing effectiveness (Phase 2)Study completedNCT02036853
What this trial is testing

An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome

Who this might be right for
Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS)
Adrian Lacy 20
Not applicableStudy completedNCT04399954
What this trial is testing

Evaluation of Ketoflo

Who this might be right for
Epilepsy IntractableGlucose Transporter Type 1 Deficiency SyndromeKetogenic Dieting
Vitaflo International, Ltd 25
Not applicableLooking for participantsNCT05085704
What this trial is testing

Brain Metabolism Observed at 3 Tesla or 7 Tesla in Health and Metabolic Disease

Who this might be right for
Glut1 Deficiency Syndrome 1Glucose Metabolism DisordersEpilepsy+4 more
Weill Medical College of Cornell University 20
Not applicableStudy completedNCT02915211
What this trial is testing

Evaluation of Keyo in Children With Epilepsy

Who this might be right for
Intractable EpilepsyGlucose Transporter Type 1 Deficiency SyndromeKetogenic Dieting
Vitaflo International, Ltd 17
Testing effectiveness (Phase 2)UnknownNCT02000960
What this trial is testing

Pilot Study of Triheptanoin in Patients With Glucose Transporter 1 Deficiency Syndrome

Who this might be right for
Glucose Transporter Type 1 Deficiency Syndrome
University of British Columbia 3
Testing effectiveness (Phase 2)Ended earlyNCT02599961
What this trial is testing

Study to Assess the Long Term Safety and Efficacy of UX007 in Participants With Glucose Type 1 Deficiency Syndrome (Glut1 DS)

Who this might be right for
Glucose Transporter Type 1 Deficiency Syndrome
Ultragenyx Pharmaceutical Inc 15
Testing effectiveness (Phase 2)Study completedNCT01993186
What this trial is testing

Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)

Who this might be right for
Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Ultragenyx Pharmaceutical Inc 36
Not applicableStudy completedNCT02013583
What this trial is testing

The Glucose Transporter Type I Deficiency (G1D) Registry

Who this might be right for
GLUT1 Deficiency SyndromeGlucose Transporter Type 1 Deficiency SyndromeGlucose Transporter Type1 (GLUT-1) Deficiency+1 more
University of Texas Southwestern Medical Center 471
Testing effectiveness (Phase 2)WithdrawnNCT02021526
What this trial is testing

Triheptanoin (C7 Oil), a Food Supplement, for Glucose Transporter Type I Deficiency (G1D)

Who this might be right for
Glucose Transporter Type 1 Deficiency SyndromeGlut1 Deficiency Syndrome
Juan Pascual
Not applicableStudy completedNCT05687474
What this trial is testing

Baby Detect : Genomic Newborn Screening

Who this might be right for
Congenital Adrenal HyperplasiaFamilial Hyperinsulinemic Hypoglycemia 1Phosphoglucomutase 1 Deficiency+121 more
Centre Hospitalier Universitaire de Liege 6,824
Not applicableWithdrawnNCT03202108
What this trial is testing

Evaluation of Krio in Children and Adults With Epilepsy

Who this might be right for
Ketogenic DietingEpilepsyGlucose Transporter Type 1 Deficiency Syndrome
Vitaflo International, Ltd
Early research (Phase 1)Study completedNCT03041363
What this trial is testing

Treatment Development of Triheptanoin (G1D)

Who this might be right for
EpilepsyGLUT1DS1Glut1 Deficiency Syndrome 1, Autosomal Recessive+4 more
Juan Pascual 12
Not applicableNo Longer AvailableNCT02018302
What this trial is testing

Post Study Continuation of C7 for G1D

Who this might be right for
Glut1 Deficiency SyndromeGlucose Transporter Type 1 Deficiency Syndrome
Juan Pascual
Testing effectiveness (Phase 2)Study completedNCT02014883
What this trial is testing

Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DS

Who this might be right for
Glut1 Deficiency Syndrome
Institut National de la Santé Et de la Recherche Médicale, France 20